Business Context and Reporting Period
This Form 8-K Current Report, filed on October 6, 2017, by Pavmed Inc. (a Delaware corporation and emerging growth company), details the results of the Company's annual meeting of shareholders held on October 4, 2017. The filing addresses corporate governance matters, including director elections, equity plan amendments, and auditor ratification.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder voting outcomes and corporate governance updates rather than financial performance data.
Material Changes and Voting Results
Shareholders approved three key proposals at the annual meeting:
- Election of Class A Directors: Ronald M. Sparks and David S. Battleman, M.D., were re-elected to serve three-year terms. Mr. Battleman was designated by Scopia Holdings LLC pursuant to a June 30, 2017 agreement.
- Equity Plan Amendment: Shareholders approved an amendment to the 2014 Long-Term Incentive Equity Plan, increasing the total number of shares available for grant from 1,951,081 to 2,951,081 shares.
- Auditor Ratification: The appointment of Citrin Cooperman & Company, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017, was ratified.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure of the voting results. The document notes that the board of directors is divided into three classes with staggered three-year terms, with Class B and Class C director terms expiring in 2018 and 2019, respectively.
Key Facts for Investor Verification
- Verify the impact of the increased share pool (2,951,081 shares) on potential future dilution.
- Confirm the continued role of Scopia Holdings LLC in board composition via the designation of David S. Battleman, M.D.
- Review the full text of the 2014 Long-Term Incentive Equity Plan (Annex A to the Proxy Statement) for specific grant terms.
- Note that the Company is classified as an emerging growth company.